

## List of Publications

### Original Articles

Number of Citations according to Google Scholar: 4624 (As of June 15, 2016)

*Reports of original investigations in refereed journals.*

1. A Bass, K Edwards, B Khatri, K Selmaj, D Margolin, L Kasten, P Sørensen Safety of Using Disease-Modifying Therapy Post-Alemtuzumab Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis in the Alemtuzumab Clinical Development Program (P6. 185) *Neurology* 2016 ;86 (16 Supplement): P6. 185
2. J Rose, M Freedman, K Edwards, P Wang, X You, S Fam Analysis of Relapse Events in the DECIDE Study Using a Novel Weighted Hurdle Model (P2. 111) *Neurology* 2016; 86 (16 Supplement): P2. 111
3. S Cohan, KR Edwards, C Chen, T Gervasi, J O'Connor, K Smoot Rebound Disease Activity Reduction in Relapsing Multiple Sclerosis Patients Transitioned From Natalizumab to Teriflunomide *Mult Scler* 2016; 22: 70-70
4. Edwards K, Freedman MS. Safety and efficacy of transitioning to teriflunomide in patients switching from other disease-modifying therapies, including natalizumab. *Mult Scler* 2015; 21: 530-530
5. Coyle PK, LaGanke C, Khatri B, Edwards K, et al. Improvements in patient-reported outcomes with teriflunomide: Week 24 interim results from the US cohort of the Teri-PRO phase 4 study. *Mult Scler* 2015; 21: 261-262
6. Travis LH, Okai A, Jackson S , Edwards K, et al. Exploring the clinical course of hair thinning associated with teriflunomide: an update to the teriflunomide real-world case series. *Mult Scler* 2015; 21: 577-577
7. Jackson A, Travis LH, Okai A, Edwards K, et al. Teriflunomide hair photography project: analysis by a dermatologist *Eur J Neurology* 2015; 22: 154-154
8. Kavak KS, Teter BE, Hagemeyer J, Weinstock-Guttman B, Edwards K, et al. Height weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. *Mult Scler* 2015; 21: 858-865
9. Edwards K, Cohan S, Thomas J et al. . An analysis of Monthly Surveillance 3T MRI in MS Patients switched from Long Term Natalizumab to Teriflunomide in a Controlled, Prospective Study *Neurology* 2015; 84 (14 Supplement): P3.295
10. Edwards K, Travis LH, Okai A, Jackson S et al. Clinical Course of Hair Thinning Associated with Teriflunomide: Case Series of Patients Who Participated in a Hair Photography Project. *Neurology* 2015; 84 (14 Supplement): P7:016
11. D Cadavid, Edwards K, Hupperts R, Drulovic J et al. BIIB0033, Anti-Lingo-1, for Treatment of Relapsing Forms of Multiple Sclerosis: Baseline Data of the Phase 2 SYNERGY Trial *Neurology* 2015; 84 (14 Supplement): P7.204
12. Miller DH, Fox RJ, Phillips JT, Edwards K, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. *Neurology* 2015; 84: 1145-1152
13. Tackenberg B, Ziemssen T, Berthele A, Edwards K, et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study *Neurology* 2015; 84: 862-862
14. Goodman AD, Bethoux F, Brown TR, Edwards K, et al. Long term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extension of two Phase 3 clinical trials *Mult Scler* 2015; 21: 1322-1331

15. Calkwood J, Cree B, Crayton H, Kantor D, Edwards K, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient-and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial *BMC Neurology* 2014; 14: 220
16. Fox E, Edwards K, Burch G, Wynn DR et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient Outcomes (EPOC) study in relapsing multiple sclerosis *Multiple Sclerosis and related Disorders* 2014; 3: 607-619
17. Coyle PK, Edwards K, Khatri BO, LaGanke C et al. Teri-PRO: Study design and US patients' baseline characteristics. *Mult Scler* 2014; 20: 102
18. Teter BE, Kavak KS, Zakalik K, Edwards K et al. Clinical characteristics and outcome measures associated with disease progression in a prospective cohort of early diagnosed MS patients. *Mult Scler* 2014; 20: 231-232
19. Edwards K, LaGanke C, Oyuela P et al. Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (P2. 201). *Neurology* 2014; 82 (Supplement 10): P2.201
20. Fox E, Edwards K, Burch J et al. Treatment Satisfaction After Switching To Fingolimod Directly From An Injectable Therapy (P7. 218). *Neurology* 2014; 82 (Supplement 10): P7.218
21. Edwards K, Cadavid D, Ranger A et al. Feasibility study of the Use of Combinatorial Chemokine Arrays to study blood and CSF in MS. *PLoS One* 2013, 8:e81007
22. Edwards K, Crayton H, Calkwood J, Agashivala N, et al. Patient-and physician-reported outcomes after therapy switch from interferon beta to fingolimod versus staying on interferon beta therapy. *Mult Scler* 2013, 19: 231-232
23. Fox E, Edwards K, Burch JG, Kim E, Pestreich L, et al. Treatment satisfaction and clinical improvement after switch to fingolimod. *Journal of Neurology* 2013, 260: S126-S126
24. Edwards K, Rosenthal B, Farmer K et al. Evaluation of Sumatriptan-Naproxen in the treatment of acute migraine headache. *Headache* 2013; 53:656-664
25. Edwards K, Goodman W. Improvement of neuropsychological function in cognitively impaired multiple sclerosis treated with natalizumab. *Int. J MS Care* 2012; 14:100-104
26. Edwards K, Goodman WA. Natalizumab Use for Neuropsychological Deficits in Relapsing Multiple Sclerosis (P04. 116) *Neurology* 2012; Meeting Abstracts 1: P7.218
27. Nielsen S, Miravalle A, Langer-Gould A, Cooper J, Edwards K, Kinkel P. B cell depletion and safety of low dose rituximab in patients with relapsing multiple sclerosis. *Mult Scler* 2012; 18: 377-378.
28. Edwards K, Rosenthal B, Farmer K et al. An Evaluation of Sumatriptan-Naproxen (Treximet) in the Treatment of Acute Migraine Headache: A Placebo Controlled, Double Blind, Crossover Study Assessing Cognitive Function. *Headache* 2011; 51:8-8
29. Edwards K, Rosenthal B, Farmer K et al. Cognitive Dysfunction at Onset of Acute Migraine. *Headache* 2011; 51:34-34
30. Teter B, Apatoff B, Coyle P, Edwards K et al. Pregnancy Related to Disability Outcomes for Women with Progressive Multiple Sclerosis. *Neurology* 2011; 76: A610-A610
31. Teter B, Apatoff B, Coyle P, Edwards K et al. Capture of Patient-Perceived Negative Mood Traits to Improve Treatment for Patients with Multiple Sclerosis. *Neurology* 2011; 76: A71-A71

32. Edwards K, Rosenthal B, Farmer K et al. Evaluation of Sumatriptan-Naproxen in the Treatment of Acute Migraine Headache: A Placebo Controlled, Double Blind, Crossover Study Assessing Cognitive Function. *Neurology* 2011; 76: A440-A440
33. I Kister, Bacon T, Chamot E, Apatoff B, Coyle P, Edwards K et al. Decrease in Individual Multiple Sclerosis Severity Scores during Follow-Up Period: Analysis of the New York State Multiple Sclerosis Consortium Dataset. *Neurology* 2011; 76: A605-A605
34. Goodman A, Brown T, Edwards K, Krupp L, Schapiro R, Cohen R, Marinucci L, Blight A. A Confirmatory Phase 3 Trial of Sustained Release Oral Fampridine in Multiple Sclerosis. *Annals of Neurology* 2010;68:494-502
35. Edwards K, Goodman WA Neuropsychological Evaluation in patients with Relapsing Multiple Sclerosis receiving Natalizumab: A Retrospective analysis *Mult Scler* 2010; 16: 1016-1016
36. Edwards K, Goodman A, Brown T, Schapiro R, Marinucci L et al. Sustained Release Fampridine Improves Walking Speed across a Wide Range of Baseline Deficits: Pooled Data from Three Placebo-Controlled Studies in Patients with Multiple Sclerosis. *Neurology* 2010; 74: A565-A565
37. Goodman A, Brown T, Edwards K, Schapiro R, Marinucci L et al. Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis. *Neurology* 2010; 74: A101-A101
38. Herbert J, Chamot E, Bacon J, Apatoff B, Coyle P, Edwards K et al. Trend towards Lowering of Multiple Sclerosis Severity Scores among More Recent Enrollees into the New York State Multiple Sclerosis Consortium *Neurology* 2010; 74: A425-A425
39. Goodman A, Brown T, Edwards K, Schapiro R, Marinucci L et al. Characteristics of Walking Speed Improvement Observed in Three Well Controlled Studies of Sustained Release Fampridine 10 mg Bid in Patients with Multiple Sclerosis. *Neurology* 2010; 74: A99-A99
40. Brown T, Goodman A, Edwards K, Schapiro R, Marinucci L et al. Response to Treatment with Sustained Release Fampridine in Patients with Multiple Sclerosis Is Independent of Baseline Patient Characteristics and Concomitant Immunomodulator Therapy. *Neurology* 2010; 74: A543-A543
41. Glantz M, Chamberlain M, Liu Q, Hsieh C, Edwards K, Horn A, Recht L. Gender disparity in the rate of partner abandonment in patients with serious medical illness. *Cancer* 2009;115;5237-42
42. Edwards K, Goodman WA, Wilken J et al Neuropsychological Evaluation in patients with Relapsing Multiple Sclerosis: Development and validation of a computerized model. *Mult Scler* 2009; 15: S230-S230
43. Edwards K, Goodman WA, Button A. F. Fampridine-SR for cognitive improvement in multiple sclerosis *Mult Scler* 2009; 15: S18-S18
44. Cohen J, Imrey P, Calabresi P, Edwards K, Eickenhorst T, Felton III W, Fisher E, Fox R, Goodman A, Hara-Cleaver C, Hutton G, Mandell B, Scott T, Zang H, Apperson-Hansen C, Beck G, Houghtaling P, Karafa M, Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. *Neurology* 2009: 72;535-541
45. Edwards K, DePalma T, Rosenthal B. Chronic cluster and associated hemifacial spasm of fifteen years duration relieved with botulinum toxin type A. *Headache* 2008; 48:S51-S51
46. Phillips J, Weinstock-Guttman B, Felton W, Edwards K et al. Safety and tolerability of the first single-use, fully integrated autoinjector for IM interferon beta-1a. *Neurology* 2008; 70 (Supplement 1): A86-A86

47. Cohen J, Imrey P, Calabresi P, Edwards K et al. Safety and tolerability of the first single-use, fully integrated autoinjector for IM interferon beta-1a. *Neurology* 2008; 70 (Supplement 1): A84-A84
48. Connor G, Edwards K, Tarsy D. Topiramate in Essential Tremor: Findings from Double-Blind, Placebo-Controlled, Crossover Trials. *Clin Neuropharmacol* 2008 Mar-Apr;31(2):97-103
49. Cohen J, Calabresi P, Chakraborty S, Edwards K, Eickenhorst T , et. al, Avonex Combination Trial (ACT) in Relapsing-Remitting MS. Rationale, Design, and Baseline Data *Mult Scler* 2008 Apr;14(3):370-382
50. Bhasin M, Rowan E, Edwards K, McKeith IG. Cholinesterase inhibitors in Dementia with Lewy Bodies – A comparative analysis. *Int J Ger Psychiatry* 2007; 22; 890 – 895
51. Edwards KR Treatment of analgesic rebound headache with rapid titration of topiramate to facilitate analgesic withdrawal. *Headache* 2007; 47(5): 758-759
52. Cohen J, Solon OH, Edwards K, Eickenhorst T , et. al, Results of the Avonex Combination Trial (ACT) *Neurology* 2007; 68 (Supplement 1): A100
53. Edwards K, Bhasin M, Rowan , et. al, A comparison of cholinesterase inhibitors for treatment of dementia with Lewy bodies *Neurology* 2007; 68 (12): A122-A122
54. Edwards K, Royall D, Hershey L et. al, Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study *Dementia and Geriatric Cognitive Disorders* 2007; 23 (6): 401-405
55. Grossberg G, Edwards K, Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease *J. Clin. Pharmacol* 2006; 46: 17S-26S
56. Cohen J, Calabresi P, Edwards K, Eickenhorst T , et. al, Rationale, design, and baseline data for the Avonex Combination Trial (ACT) *Age* 2006; 18 : 55
57. Edwards K. Rivastigmine reduces need for neuropsychotherapeutics in AD *InPharma* 2005; 1504: 10
58. Edwards KR, Koumaras B, Chen M, Gunay I, Mirski D. Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer's Disease: Results of a 52-Week Open-Label Study *Clinical Drug Investigation* 2005: 25 507-515
59. Previti, M, Chamberlain M, Kesari S, Edwards K et al. Levetiracetam (LEV) monotherapy in patients with primary brain tumors (PBTs): Efficacy, side effects, and CSF and plasma pharmacokinetics. *Neuro-Oncology*, 2005; 7: 376.
60. Edwards K, O'Connor JT, Gorman C . Switching from donepezil or rivastigmine to galantamine in clinical practice *J of American Geriatrics Society* 2004; 52: 1965-1965
61. Sadowsky C, Edwards K, Etemad B et al Maintaining effective treatment in dementia: A case series on patients switched to rivastigmin *Primary Care Psychiatry* 2004;9: 71-75
62. Edwards K Galantamine in the treatment of dementia with Lewy bodies: an interim 24 week assessment *Neurobiology of Aging* 2004; 25: S21
63. Edwards K, Dreyer M. Novel therapeutic agents: Botulinum toxin type A for failed back syndrome. *The Journal of Pain* 2004; 5:S63
64. Edwards K, Dreyer M. Novel therapeutic agents: Botulinum toxin type A for refractory neck pain. *The Journal of Pain* 2004; 5:S62
65. KR Edwards, MJ Glantz, T Bator, J Button Levetiracetam levels in human cerebrospinal fluid: a controlled, dose ranging pharmacokinetic study. *Neurology* 2004; 62: A118

66. M Glantz, L Recht, K Edwards Pre-treatment homocysteine levels correlate strongly with neurologic morbidity following fractionated external beam cranial irradiation (RT) in patients with brain tumors. *Neurology* 2004; 62:A475
67. K Edwards, L Hershey, M Farlow, D Lichter, S Johnson Galantamine for the treatment of dementia with Lewy bodies *Movement Disorders* 2004; 19:S336-S337
68. Edwards K, O'Connor JT, Button J Levetiracetam for the treatment of trigeminal neuralgia *Epilepsia* 2004;45, 306-306
69. Edwards K, Glantz M The pharmacokinetics of levetiracetam in human cerebrospinal fluid and serum: A controlled, dose-ranging study in malignant brain tumor patients *Epilepsia* 2004: 45 (Suppl 7), 121
70. Edwards K, Hershey L, Wray L, Bednarczyk E, Lichter D, Farlow M Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis *Dementia and geriatric cognitive disorders* 2004;17 (Suppl. 1), 40-48
71. Edwards K, O'Connor J, Button J, Goodman WA, Norton J Rivastigmine Can Stabilize Cognitive and Behavioral Decline in Patients with Probable Alzheimer's Disease who Worsen on Donepezil Treatment *The Eleventh International Congress* 2003: PB-029
72. Edwards K Galantamine in the Management of Dementia with Lewy Bodies: A 24-week, Open-Label Study *The Eleventh International Congress* 2003:PB-027
73. K Edwards Switching from Donepezil or Rivastigmine to Galantamine in Clinical Practice *The Eleventh International Congress* 2003:PB-028
74. Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the Preventive Treatment of Episodic Migraine: A Comorbid Analysis From Pilot, Doubled-Blind, Placebo-Controlled Trials. *CNS Spectrums*. 2003; 8:428-432
75. Edwards K, O'Connor JT, Gorman C et al A clinical perspective of the safety, tolerability, and efficacy of galantamine in patients switched from donepezil or rivastigmine. *Journal of American Geriatrics Society* 2003; 51 (4), S126-S126
76. Edwards K, O'Connor JT Switching from donepezil or rivastigmine to galantamine in clinical practice *International Psychogeriatrics* 2003; 15:253-254
77. Glantz M, Edwards K The Epidemiology and Management *Cancer Neurology in Clinical Practice* 2002; 62: 9
78. Edwards K, O'Connor JT, Goodman W Rivastigmine is well tolerated on a four-week titration schedule *Neurobiology of Aging* 2002; 23 (1): S97-S97
79. Edwards K, Goodman W, Anand R et al Effect of Alzheimer's disease severity on psychotropic drug use and behavior in nursing home patients treated with rivastigmine *Neurobiology of Aging* 2002; 23 (1):S78-S78
80. Edwards K, O'Connor J, Goodman W, Button J Rivastigmine can stabilize cognitive and behavioral decline in patients with probable Alzheimer's disease who worsen on donepezil treatment *Neurobiology of Aging* 2002; 23 (1):S79-S79
81. Edwards K, O'Connor JT Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors *Journal of the American Geriatrics Society* 2002; 50 (6):1165-1166
82. Edwards KR, O'Connor J, Norton JA. Rivastigmine in Patients with Vascular Risk Factors and Probable Alzheimer's Disease: Analysis of 29 Patients After 2 Years of Treatment. *J Neurol Sci*. 2002;203-204:294-295

83. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M, and the Topiramate TPS-TR Study Group. Topiramate titration and tolerability. *Ann Pharmacotherapy* 2001; 35:173-179
84. Sherman D, Bees A, Easton JD, et al. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial *Neurology* Oct 2001; 57(8): 1428-1434
85. Edwards KR, Hulihan J, Kraut L, Olson WH, Kamin M. Efficacy of the antiepileptic topiramate in the preventative treatment of episodic migraine: A pooled analysis from 2 randomized, double blind, placebo-controlled trials. *Advanced Studies in Medicine*, John Hopkins University School of Medicine 2001; 3:101-104.
86. Edwards KR, Sackellares JC, Vuong A, Hammer AE, Barrett PS. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double-Blind Comparison with Valproate. *Epilepsy & Behavior* 2001; 2: 28-36.
87. Edwards KR, Norton JA, Behnke M, Khoury K. Comparison of Intravenous Valproate versus intramuscular dihydroergotamine and Metocloperamide for acute treatment of Migraine Headache. *Journal of Head and Face Pain* 2001; 41:976-980.
88. Clark WM, Hourihane M, Doherty A, et al.: "A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients" *Neurology*. 2001 Nov 13; 57(9): 1595-602.
89. Edwards K, Anand R, Koumaras B, Hartman R Effect of Alzheimer's disease severity on psychotropic drug use and behavior in nursing home patients treated with rivastigmine *Gerontologist* 2001; 41: 123-124
90. Edwards K, Goodman W, Anand R et al Effect of Alzheimer's disease severity on psychotropic drug use and behavior in nursing home patients treated with rivastigmine *Gerontologist* 2001; 41:123-124
91. Cross N, Glantz M, Cole BF, Cobb J, Recht L, Edwards K, Chamberlain M Dramatically increased frequency of divorce and separation in female but not male patients with gliomas *Neurology* 2001; 56 (8):A477-A477
92. Edwards K, Goodman W, Khoury KN, Cross N, Norton J, Lewis C Flexible titration reduces side effects of rivastigmine. *Journal of the American Geriatrics Society* 2001;49 (4), S92-S92
93. Edwards K, Goodman W, Khoury KN, Cross N, Norton J, Lewis C Rapid changeover from donepezil to rivastigmine well tolerated. *Journal of the American Geriatrics Society* 2001; 49 (4), S91-S92
94. Edwards K, Sackellares JC, Vuong A, Hammer AE, Barrett PS Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate *Epilepsy & Behavior* 2001; 2 (1): 28-36
95. Biton V, Edwards K, Montouris G et al Topiramate titration and tolerability *Annals of Pharmacotherapy* 2001; 35:173-179
96. Glauser, TA, Nigro, M, Sachedeo, et. al.: Adjunctive therapy with oxcarbazepine in children with partial seizures. *Neurology* 2000; 54:12:2237-2244
97. Ritter, F, Glauser, TA, Elterman, RD, et.al: Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. *Epilepsia*, 2000;41:1:S82-85
98. Edwards K, Hulihan J, Kraut L, Kamin M Efficacy of the anticonvulsant topiramate in the prophylactic treatment of episodic migraine: A pooled analysis from two randomized, placebo-controlled trials *Annals of Neurology* 2000; 48: 486-486

99. KR Edwards, MJ Glantz, J Button, JA Norton, T Whittaker, N Cross Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo controlled study *Neurology* 2000; 54:A81-A81
100. KR Edwards, MJ Glantz, P Shea, JA Norton, N Cross A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. *Cephalalgia* 2000; 20: 316
101. G Dyker, KR Edwards, PB Fayad, JT Hormes, KR Lees Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke *Stroke* 1999; 30: 2038-2042
102. Dyker AG, Edwards KR, Fayad PB, Hormes JT, Lees KR. A Safety and Tolerability Study of Aptiganel HCl in Patients After an Acute Ischemic Stroke. *Stroke*, 1999; 30:2038-2042.
103. Edwards KR. Peripheral Neuropathy and Postherpetic Neuralgia. *Clin.Geriatrics* 1999; Suppl: 3-10.
104. Elterman, RD, Glauser, TA, Wyllie, E, et.al.: A double blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. *Neurology*, 1999; 52:7:1338-1344
105. KR Edwards, J Cummings, R Anand, R Hartman, B Koumaras, J Messina Behavioral effects of rivastigmine: Interim results from the neuropsychiatric inventory-nursing home version in nursing home patients with Alzheimer's disease. *Annals of Neurology* 1999; 46:453-453
106. Backonja M, Beydoun A, Edwards K, Schwartz SL Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial. *Survey of Anesthesiology* 1999; 43:236-237
107. KR Edwards, V Santarcangelo Sodium valproate for the treatment of chronic daily headaches. *Cephalalgia* 1999;19:453-453
108. K Edwards, V Santarcangelo, P Shea, J Edwards Intravenous valproate for acute treatment of migraine headaches. *Cephalalgia* 1999;19 : 356-356
109. RC Sachdeo, K Edwards, H Hasegawa, W Rosenfeld, B Abou-khalil Safety and efficacy of oxcarbazepine 1200 mg day in patients with recent onset partial epilepsy *Neurology* 1999;52 :A391-A391
110. K Edwards, M Behnke, V Santarcangelo Intravenous valproate for abortive treatment of acute migraine headache. Is there an anti-convulsant mechanism? *Epilepsia* 1999; 40:36-36
111. KR Edwards, P Shea, M Behnke Acute treatment of migraine headache with intravenous valproate (Depacon) *Epilepsia* 1999;40:143-143
112. KR Edwards New Treatments for Diabetic Neuropathy *Home Healthcare Consultants* 1999; 6:24-26
113. M Backonja, A Beydoun, KR Edwards, SL Schwartz, V Fonseca, M Hes Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial *Jama* 1998; 280 (21): 1831-1836
114. KR Edwards, MJ Glantz, J Button, J Norton, T Whittaker An evaluation of topiramate in the management of painful diabetic neuropathy 17th Annual Science Meeting of the American Pain Society, San Diego, CA 1998
115. KR Edwards, MS Hes, LK LaMoreaux, EA Garofalo, EM Koto Gabapentin (Neurontin®) for pain associated with diabetic peripheral neuropathy: A double blind, placebo-controlled study *Neurology* 1998;50 (4):A378-A379
116. D Potter, KR Edwards Potential role of topiramate in relief of neuropathic pain *Neurology* 1998;50 (4):A255-A255

117. K Edwards, A Block, B Richardson, D Potter A community hospital experience with aptiganel hydrochloride for acute ischemic stroke on hospital utilization outcome *Journal of Stroke and Cerebrovascular Diseases* 1997; 6 (6), 460
118. K Edwards, M Kamin The beneficial effect of slowing the initial titration rate of Topiramate *Neurology* 1997; 3:1042-1042
119. Potter DL, Edwards K, Brown DS An open label study of tacrine for treatment of residual cognitive defects in patients with traumatic brain injury *Neurology* 1997; 48: 1069-1069
120. KR Edwards Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial *Neurology* 1996; 46(2): 62002-62002
121. KR Edwards Felbamate and tremor *Neurology* 1995; 45(10): 1951-1951
122. S Schachter, V Biton, S Boellner, K Edwards, K Cybulski, V Shu Safety and efficacy of Tiagabine HCL Monotherapy in the treatment of partial seizures-high dose versus low-dose *Epilepsia* 2005; 36:S148-S148
123. MJ Knapp, DS Knopman, PR Solomon, KR Edwards A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease *Jama* 1994; 271 (13): 985-991
124. PR Solomon, ME Groccia-Ellison, Flynn D, KR Edwards Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine. *Behavioural Neurosciences* 1993; 107(2):271
125. KR Edwards, CM Poser, SB Filskov, JM Peyser Control Groups for Multiple Sclerosis Tests-Reply *Archives of Neurology* 1981; 38(5): 325-325
126. Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive functions in multiple sclerosis patients. *Arch Neurol* 1980; 37:577-579
127. Peyser JM, Edwards KR, Poser CM. Psychological profiles in multiple sclerosis patients: A preliminary investigation. *Arch Neurol* 1980; 37:437-440
128. KR Edwards Cerebral arteritis associated with ulcerative colitis *Neurology* 1979; 29(3): 425-425
129. Roman-Campos G, Edwards KR. Painful ophthalmoplegia: Oculomotor nerve palsy without mydriasis due to compression by aneurysm. *Headache* 1979; 19:43-46
130. Edwards K. The hemorrhagic complications of cerebral arteritis - reply. *Arch Neurol* 1978; 35(6):397-397
131. Poser, CM., Edwards, KR.: Acute intermittent porphyria presenting as a monoparesis. *Arch Neurol* 1978; 35: 550
132. Edwards K. The hemorrhagic complications of intracranial arteritis. *Arch Neurol* 1977; 34:549-552
133. Edwards K, Gowitt GT, Rollins RL. State mental hospital referrals: patient abandonment by local medical resources. *N Carol Med J* 1974; 35:151-155
134. Slotkin T, Edwards K. The effects of reserpine on the content and properties of rat adrenal medullary storage vesicles. *Biochem Pharmacol* 1973; 22:549-560